contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


immunovia-ab-invitation-to-immunovias-q2-presentation-2

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Immunovia is a biotechnology company. The company's research and development is focused on molecular diagnostics, where the business focuses on driving the development and change of current working methods for diagnosing complex cancers and immune diseases. The vision is to establish blood-based tests to be able to identify different types of pancreatic cancer at an early stage. The company was founded in 2007 and is headquartered in Lund.

Immunovia

LUND (SWEDEN) - Immunovia will publish its second quarter 2024 results on August 5, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day...

<div class="abstract">LUND (SWEDEN) - Immunovia will publish its second quarter 2024 results on August 5, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com</div>&nbsp;&nbsp;Jeff Borcherding, CEO and President, and Karin Almqvist Liwendahl, CFO, will present on Immunovia's development. The presentation will be held in English and be followed by a Q&amp;A session. You are welcome to join via webcast or phone, see details below.Telephone numbers and webcastCall any of the numbers below to participate via telephone. Please dial in a few minutes before the presentation starts.Sweden: +46 (0)8 5051 0031United Kingdom: +44 (0) 207 107 06 13United States: +1 (1) 631 570 56 13Link to the webcast: creo-live.creomediamanager.com/9b8512c0-acbd-4f80-bb26-08165af4fa28&nbsp;(<a href="https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Flink.edgepilot.com%2Fs%2Fb5f6e40c%2Fpw3hzes_XkqnzS5LxdNKaQ%3Fu%3Dhttps%3A%2F%2Fcreo-live.creomediamanager.com%2F9b8512c0-acbd-4f80-bb26-08165af4fa28&amp;data=05%7C02%7Cemmy.arebo%40immunovia.com%7C50fbbd2e700243a418e608dc8c57ffc9%7C4108bd4b5f9f40d6bfffa07cc8682f85%7C0%7C0%7C638539556826578230%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=0bT4kdwhZCrMLBAuycwtRUW18d7wp5t2INWdRUkKANI%3D&amp;reserved=0">https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Flink.edgepilot.com%2Fs%2Fb5f6e40c%2Fpw3hzes_XkqnzS5LxdNKaQ%3Fu%3Dhttps%3A%2F%2Fcreo-live.creomediamanager.com%2F9b8512c0-acbd-4f80-bb26-08165af4fa28&amp;data=05%7C02%7Cemmy.arebo%40immunovia.com%7C50fbbd2e700243a418e608dc8c57ffc9%7C4108bd4b5f9f40d6bfffa07cc8682f85%7C0%7C0%7C638539556826578230%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=0bT4kdwhZCrMLBAuycwtRUW18d7wp5t2INWdRUkKANI%3D&amp;reserved=0</a>)A recording of the presentation will be available on Immunovia's website.For more information, please contact: Karin Almqvist Liwendahl CFO kain.almqvist.liwendahl@immunovia.com +46 70&nbsp;911 56 08Immunovia in briefImmunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.&nbsp;&nbsp;Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit &nbsp;(<a href="http://www.immunovia.com/">http://www.immunovia.com/</a>)www.immunovia.com&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ###

Stay up to date with our newsletter